NCT04815031View on ClinicalTrials.gov

Drug Use Investigation of COMIRNATY Intramuscular Injection

CompletedOBSERVATIONAL

Enrollment

14,570

Participants

Timeline

Start Date

March 20, 2021

Primary Completion Date

January 27, 2023

Study Completion Date

January 27, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

BNT162b2

Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.

Trial Locations (1)

1518589

PfizerLocal Country Office, Tokyo